initi outperform commerci
biopharma make
initi coverag genmab outperform rate tp genmab
danish biopharma found novel antibodi platform success built
partnership novarti arzerra darzalex provid genmab cash
valid expand antibodi discoveri strategi invest thesi move beyond
darzalex think forecast well reflect cse peak royalti
focu switch pipelin prepar becom commerci biopharma compani
valuat underpin darzalex remain uncertainti surround coronaviru
impact pharma howev believ genmab better place peer
given innov platform strong predict cash flow anti-canc drug
darzalex npv underpin darzalex current share price
ofatumumab sale underappreci believ next near-term sale opportun
come launch ofatumumab partner novarti second
launch multipl sclerosi genmab receiv flat royalti sale think
investor focus competit establish ocrevu roch
overlook growth ms market forecast sale ofatumumab
po doubl consensu
multipl pipelin updat drive potenti upgrad genmab
reinvest darzalex incom leverag platform gener unpartn
asset pipelin momentum build see data tisotumumab
vedotin tv cervic cancer potenti first commerci asset duobody-
b-cell malign anticip launch genmab expect
potenti partnership net present valu npv unpartn product
partnership potenti unlock valu
catalyst result may tv cervic data sc darzalex
approv
risk includ pipelin failur hinder sale
valuat develop biopharma view pharmavalu npv best
methodolog captur valu pipelin genmab trade ev/npv
discount eu specialti peer cs holt warrant price
valuat metric
price-to-earnings rel local market
price rel chart measur perform
omxc close
spot exchang rate
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
genmab danish biotech compani develop human monoclon
antibody-bas therapi area therapeut interest includ
oncolog well autoimmun diseas includ rheumatoid arthriti
multipl sclerosi
scenario give valuat
scenario base stronger sale darzalex
ofatumumab pipelin success
grey scenario give valuat grey
scenario base weaker sale darzalex
ofatumumab pipelin success
price rel chart measur perform omxc close
spot exchang rate
price credit suiss estim
dkkbn reveneu revenu result dkkbn oper result oper result bn darzalex darzalex bn ofatumumab ofatumumab avgalmirallipsengenmablundbeckmerck kgaaucbviforgrifolsorionrecordatipharmavalu npv evotheroth health/evnpv mktd /evnpv pipeline/evless attract charl martineau univers toronto april
tabl content
invest genmab
outperform rate tp
strong growth profil rel specialti pharma
differ product characterist clear winner
forecast doubl consensu
darzalex well reflect consensu provid solid valuat floor
subq dose add conveni
indic offer increment sale low probabl
competit intens unlik replac darzalex
enapotamab vedotin potenti refractori biomark select patient
epcoritamab subcutan bispecif b-cell malign
esg measur less critic biopharma
genmab corpor govern larg line peer differ
ceo compens appear averag vs peer
account qualiti look good holt vs eu specialti region peer
initi genmab outperform rate target price
pivot discoveri commerci biopharma genmab profit
danish biotech compani found proprietari antibodi technolog platform
high-throughput screen success built partnership novarti
arzerra chronic cell leukemia cll darzalex multipl myeloma
provid genmab signific cash valid expand antibodi discoveri
strategi recent year key stori big darzalex royalti incom could
grow howev believ genmab invest thesi move beyond darzalex
think forecast larg well reflect although
consensu due impact coronaviru focu switch pipelin
compani prepar take next step becom commerci biopharma
compani build experienc commerci team
valuat underpin darzalex valuat think mani investor may ask
invest genmab given coronaviru risk consid signific
uncertainti surround pandem address up-front move
fundament busi importantli genmab strong predict cash flow
darzalex establish cornerston multipl myeloma treatment npv
npv current share price underpin valuat
ofatumumab sale underappreci believ next near-term sale opportun
come mid-year launch ofatumumab novarti second launch
ms genmab receiv flat royalti sale think investor overli focus
competit roch establish ocrevu overlook growth ms
market segment use still modest ms market share older
interferon avonex rebif betaseron copaxon share forecast
sale vs consensu account genmab
npv novn npv context ocrevu peak sale
multipl near-term pipelin updat drive potenti upgrad momentum
pipelin build next month genmab multipl pipelin catalyst
drive potenti earn upgrad conserv revenu forecast
tisotumumab vedotin see phase data tisotumumab vedotin cervic
cancer potenti genmab first intern market commerci asset
subcutan darzalex see like approv subcutan darzalex mid-
help patient conveni unlock proport
prescrib prescrib due high burden iv administr
 partnership b-cell malign
highli anticip catalyst genmab expect potenti partnership announc
believ partnership well-establish compani would well receiv
ev/npv valuat look inexpens rel specialti pharma relev
biotech compani mani pharma biopharma stock coverag
inexpens rel absolut valuat genmab rank third cheapest behind
almiral ipsen pharmavalu ev/npv eu specialti pharma see figur
stock trade ev/npv versu relev peer
european specialti pharma peer
risk ofatumumab global launch hinder due lower darzalex
sale cancer treatment cancel stronger competitor
efficaci safeti data vs darzalex multipl myeloma failur pipelin
product clinic trial
invest genmab
gener amid pandem see european pharmaceut sector
highli defens driven underli secular demand good innov high cash flow
strong balanc sheet within believ genmab attract profil
rel biopharma specialti pharma peer base
novel antibodi technolog good track record genmab proprietari
antibodi develop platform gener multipl different-format antibodi
bispecif antibodi drug conjug technolog yield arzerra ofatumumab
darzalex daratumumab genmab believ technolog advantag
tradit mab creat mab greater tissu penetr theori enhanc
clinic effect addit technolog enabl fast process even commerci
manufactur scale outperform rate base view uniqu
platform allow genmab consist keep gener potenti drug candid
strong predict cash flow volatil environ believ higher
sustain cash flow provid compani greater flexibl darzalex ocrevu
give genmab strong predict cash flow limit risk unlik biotech
compani requir consist refund earli biopharma compani
expect genmab pay dividend reinvest pipelin figur
figur european specialti pharma futur free cash flow use
strong reinvest potenti base histor record genmab
distinct posit profit yet commerci think genmab
reinvest add royalti revenu base figur set chang market
cap seven year ratio spend compar disclos peer
disconnect market cap npv chart show genmab highest
increas market cap spend compar peer
majorseu cs use adj flowdividendr adj tax capitilis dshare repurchaseacquisitionsunalloc fcfadj charl martineau univers toronto april
figur genmab strongest market cap perform vs spend
essenti drug exposur believ revenu non-essenti elect procedur
risk hospit accommod increas bolu acut patient need
treatment respiratori symptom believ genmab market blood cancer
medicin darzalex daratumumab arzerra ofatumumab essenti case
darzalex mani patient elderli may choos miss cycl believ
like short-term effect patient unlik stop use darzalex
cur regimen furthermor pipelin therapi ofatumumab multipl sclerosi
immune-compromis patient may prefer home subcutan
dose figur show proport sale split essenti drug statu
figur european specialti pharma compani portfolio exposur essenti medicin statu
geneticsswedish orphanmorphosysalkexelixisbluebirdipsenincyteionisagiosnektarbiomarinjazzlundbeckunitedalkerm market cap yr kgaaorionrecordatiucbvifortotalproport drug sale split treatment group gp-chroniccancer- injectioncancer- oralspecialist-criticalhospitalvaccinesgp-episodicspecialist-non criticalelect charl martineau univers toronto april
sale ep growth well ahead averag genmab one expens
stock price-to-earnings howev compani non-commerci product price-to-earnings
appropri measur valu genmab fulli captur pipelin valu
becom commerci compani note sale ep cagr
well ahead relev peer respect eu
specialti pharma
potenti risk delay ofatumumab launch impact valuat like
minim highlight bristol myers-squibb delay launch zeposia
ozanimod oral ms drug due outbreak possibl novarti
ofatumumab launch current plan middl year given
current market environ howev note ofatumumab global launch
delay year peak sale declin calcul npv contribut
would fall less
outperform rate tp
valuat valu genmab product sum-of-the-part pharmavalu npv valuat
biotech gener rel limit earn think pe valuat fulli
captur valu pipelin pharmavalu npv genmab
indic potenti upsid therefor support outperform rate
 darzalex cse peak sale believ darzalex provid valuat
floor investor darzalex npv driven royalti revenu risk-adjust
darzalex sale averag royalti forecast broadli
line consensu lower due impact
coronaviru account valu genmab npv
sale consensu pandem would account
valu
 ofatumumab cse peak sale second valu driver risk-
adjust ofatumumab sale flat royalti rate forecast sale
doubl consensu think investor overli
focus competit establish ocrevu roch overlook
growth ms market context ocrevu peak sale
ofatumumab npv
proprietari partner pipelin believ phase
tisotumumab vedotin tv data cervic cancer partnership
b-cell malign next value-unlock event
believ total pipelin ex-ofatumumab account
npv npv unpartn product
pharmavalu ev/npv genmab rank third cheapest behind almiral ipsen
pharmavalu ev/npv vs eu specialti pharma see figur stock trade
ev/npv versu european specialti pharma peer
strong growth profil rel specialti pharma
above-averag sale ep growth sale ep growth
slightli consensu due higher ofatumumab sale see figur
figur howev rel specialti pharma name growth well
avgalmirallipsengenmablundbeckmerck kgaaucbviforgrifolsorionrecordatipharmavalu npv evotheroth health/evnpv pipeline/evless attract dkkbn reveneu revenu dkk ep ep charl martineau univers toronto april
price-to-earnings genmab one expens stock price-to-earnings howev
development biotech stock price-to-earnings appropri measur valu genmab
view fulli captur pipelin valu becom commerci compani
above-averag sale ep growth highlight sale ep cagr
respect well ahead relev peer eu specialti
price compani data credit suiss estim estim
scenario yield valuat grey
believ posit risk/reward current level addit grey valuat
current share price flex
base case assum darzalex sale flex assumpt
sale downsid upsid
base case assum ofatumumab sale flex assumpt
sale upsid downsid
pipelin success failur
figur /grey scenario genmab dkk
holt linker price
use holt linker appli valuat methodolog explicit cs forecast
follow sector-standardis sale growth rate line peer
also model period use averag forecast ebitda reflect
period group infrastructur place beyond revert holt
core fade assumpt addit use standardis discount rate case
versu holt default use averag across
univers eu specialti pharma compani see greater similar
compani local market therefor use sector-bas
rather country-bas discount rate remov excess cash balanc
sheet assum reinvest rather dividend weigh appar
return use sector-standard holt linker suggest warrant price
month current price
note balanc sheet holt versu
ifr holt capitalis past add report balanc
sheet strong asset growth evid figur reflect share issuanc
mileston incom ad cash expect
decreas revenu ebitda margin also evid figur reflect lack
signific one-tim commerci sale mileston incom
compar sale mileston boost revenue/margin
given transit genmab undertak develop stage compani fund
royalti toward fulli integr specialti compani sale infrastructur
ultim oper margin inher unpredict base current sale
forecast flex mid-term ebitda margin would flex warrant
price
figur holt linker genmab
current price dkk price dkk date growth parallel point chang forecast dec growth mgn turn rate grth book pe credit suiss analyst scenario datagenmab a/ gmab ebitda margin parallel point chang downsidewithin upsidesourc credit suiss holt cfroi holtar trademark regist trademark credit suiss group ag affili unit state countri growth turn cfroihistor transact cfroiforecast cfroiforecast cfroidiscount ratecfroi discount rate asset growth rateforecast growthforecast growthnormalis growth rateasset growth charl martineau univers toronto april
cse peak sale forecast vs consensu
npv npv
cs comment data competit vs market therapi think investor
focus much competit roch establish ocrevu overlook
growth ms market segment
think investor overlook opportun ofatumumab human monoclon
market develop novarti second-lin regimen chronic lymphocyt
leukemia arzerra file relaps remit multipl sclerosi pdufa june
genmab entitl flat royalti regulatori sale mileston novarti
fulli respons cost associ develop commercialis ofatumumab
approv ofatumumab us expect june europ
phase asclepio ii studi show ofatumumab highli statist
signific clinic meaning reduct relaps
compar aubagio terifluomid sanofi
primari endpoint annualis relaps rate impress patient treat
ofatumumab show annual relaps rate compar
aubagio asclepio ii respect current standard
beta correspond reduct phase opera ii
studi caveat usual concern cross-trial comparison believ
asclepio data encourag
howev key secondari endpoint look light vs ocrevu arr strong
ms therapi today clinician compar long-term outcom diseas
progress disabl endpoint ocrevu appear advantag
data show month ofatumumab vs
month ofatumumab vs compar
opera ii ocrevu show month vs
month vs
highlight cdp ofatumumab month statist signific
compar ocrevu progress appear slightli inferior
 chang brain volum asclepio differ
ofatumumab aubagio term slope brain volum chang two-
year studi contrast ocrevu roch report reduct rate
safeti look line prior studi see obviou seriou advers event
signific differ safe profil two drug
activecomparisonactivecomparisonactivecomparisonactivecomparisonasclepio statist significantreduct number gd lesionschang brain reduct vs ifn- reduct vs aubagio vs aubagioocrevu vs interferon betaannualis relaps rate confirm diseas charl martineau univers toronto april
differ product characterist clear winner
subcutan vs iv administr ofatumumab subcutan inject
novarti believ benefit at-hom administr ocrevu taken
out-pati set intraven dose believ neurologist infus
centr may prefer intraven infus vs at-hom administr reimburs
system provid incent administ set
monthli vs everi month dose ofatumumab once-monthli administr
compar everi month ocrevu subcutan dose provid
flexibl patient want howev discuss opinion leader
kol state prefer dose coincid
patient neurolog checkup ms patient also often symptom-fre remiss
want feel ill dose allow drug home
monthli remind diseas
ofatumumab less deep b-cell suppress ofatumumab less deep b-cell
suppress ocrevu given fast b-cell replet potenti preserv immun
believ ofatumumab could favour women think start famili
ms patient women risk-avers doctor patient howev
need see present ectrim data present roch
support theori deep b-cell suppress contributor ocrevu efficaci
forecast doubl consensu
growth ms market like eros ocrevu share cross-trial
comparison drug advantag ofatumumab ocrevu disabl
progress measur clear conclus formid high-efficaci
ms treatment expect drug gain share overal ms market believ
novarti help ms market grow vs eat roch exist share
use still modest overal ms market older interferon avonex
betaseron rebif copaxon share howev use grow rapidli
new patient patient chang therapi receiv ocrevu
benefit novarti ms expertis infrastructur assum ofatumumab gain
approv ms genmab benefit novarti strong presenc ms
think would bolster growth class overal
ofatumumab current model probabl peak sale
account total novn npv assumpt reflect ocrevu first-to-market
domin posit well infus typic prefer patient
addit unlik ocrevu ofatumumab benefit bolu ppm patient
ofatumumab forecast consensu
darzalex well reflect consensu
provid solid valuat floor
cse peak sale multipl myeloma probabl success
indic probabl success sale forecast broadli line
consensu lower year disrupt
npv provid valuat base npv
cs comment believ next catalyst sc dose could open
bigger proport prescrib pipelin competit intens darzalex move
earlier line therapi help buffer sale
past year genmab share price perform strongli driven darzalex
daratumumab posit clinic data multipl myeloma approv sale upgrad
darzalex sale perform remain critic deliv fund genmab next wave
 invest investor sentiment
multipl myeloma type blood cancer form white blood cell plasma cell
typic produc antibodi fight infect foreign bodi cancer cell build
bone marrow eventu crowd healthi blood cell
partner janssen divis johnson johnson darzalex
technolog multipl myeloma mm cell overexpress block induc
tumour cell death number mechan
sinc approv darzalex establish key multipl myeloma mm
backbon therapi physician approv across line therapi differ
combin figur us physician tend prefer revlimid lenalidomid
combin dexamethason dex eu row velcad bortezomib dex
prefer combin
sever late-stag studi mm transplant eligible/inelig
smolder mm amyloid light chain al amyloidosi on-going next key catalyst
fda approv subcutan formul darzalex mm expect mid-
confirm recent confer call
monotherapi siriu novemb d-vd d-rd castor pollux june d-pd eqquuleu may transplant inelig d-vmp alcyon februari dosingjun transplant ineligibled-rdmaiaseptemb transplant eligibled-vtdcassiopeiaapril monotherapi siriu februari d-vd d-rd castor pollux june transplant inelig d-vmp alcyon decemb dosingnovemb transplant charl martineau univers toronto april
darzalex estim broadli line consensu
key investor consider underpin darzalex sale share across
line therapi evolv time long darzalex use across
line therapi key debat whether darzalex see greater shift earlier line
therapi becom entrench open potenti larger volum longer
durat treatment detail basi darzalex forecast appendix
proprietari product includ look clinic data across differ line
mm therapi patient model durat assumpt
like impact sale short term forecast lower
sale due coronaviru mani mm patient elderli may choos miss
cycl fear catch coronaviru hospit howev believ like
short-term effect patient unlik stop use darzalex given
long-term sale broadli line expect sale forecast
consensu estim believ darzalex sale could
set
outlin sensit sale earn forecast chang averag
durat use month averag penetr
figur darzalex sale sensit analysi
subq dose add conveni
figur tp sensit darzalex mm penetr
durat treatment
current iv administr darzalex take approxim seven hour
first infus three five hour futur infus cut time spent
hospit genmab approv split dose darzalex two consecut day
make conveni patient howev dose time still burden
patient prescrib
given inconveni dose regimen genmab subcutan dose version darzalex
develop offer significantli quicker infus time premix
formul co-formul recombin human hyaluronidas enabl dose
minut data phase pleiad phase columba show
subcutan formul darzalex non-inferior intraven formul
similar safeti base data subcutan formul file fda
ema approv respect
bn darzalex darzalex averag durat treatment month mm penetr mm penetr durat treatment charl martineau univers toronto april
reflect approv subcutan dose forecast assum
price howev dose come higher price forecast could rise
subq dose enhanc competit profil
shorter infus time subcutan dose reduc dose time sharpli
hour iv infus also believ shorter administr time
benefit darzalex earlier line therapi longer mainten treatment
asymptomat smolder mm patient infus time significantli better
competitor pipelin product offer quicker option elderli and/or frail patient
sarclisa recent approv expect administr time
first infus decreas second infus
third infus howev sanofi note darzalex requir premed steroid
antihistamin dampen infus reaction take
observ period first administr know sarclisa requir
monitor period label advis premed minut infus
iv diphenhydramin although sure long would take
figur administr time molecul
lower patient prescrib healthcar system burden iv dose logist
burden requir two nurs shift long period infus chair number
infus chair commun care centr limit problem could solv
faster administr time believ subcutan administr could provid
opportun doctor prescrib darzalex genmab state
physician prescrib darzalex iv administr long
lower risk infus reaction highlight darzalex high rate infusion-
relat reaction first daratumumab infus relat treatment durat
castor pollux trial infusion-rel reaction occur
patient respect respect occur first
infus columba trial lower rate infusion-rel reaction observ
arm receiv subcutan administ formul daratumumab
compar iv vs advers event also lower sc sc
arm vs iv arm
columba studi dataorrctroughsc daratumumab mg/ml iv daratumumab mg/ml ctrough maximum trough concentr daratumumab day third treatment cyclemoleculeadminitrationdos mg/kg first infusionsubsequ charl martineau univers toronto april
indic offer increment sale
low probabl
sever on-going late-stag studi mm combin bortezomib
lenalidomid dex transplant eligible/inelig smolder mm amyloid light chain
al amyloidosi solid tumour forecast addit sale indic
smolder multipl myeloma smolder mm earli precursor mm
usual progress slowli activ mm diseas asymptomat often diagnos
serendipit follow blood test current smolder mm patient gener
untreat activ myeloma develop genmab shown mix result high-risk
intermediate-risk patient phase ii centauru trial one co-
primari endpoint met co-primari endpoint median month met cr
met phase aquila trial on-going data due
forecast peak sale sale smolder mm probabl success
non-multipl myeloma indic al potenti first
light-chain amyloidosi al light-chain amyloidosi common form
system amyloidosi case year bone marrow disord lead
amyloid accumul organ tissu insolubl amyloid fibril deriv
immunoglobulin light chain produc plasma cell current treatment includ
treatment regimen mm cure liver transplant stop
product transthyretin lead amyloid accumul phase andromeda
data al amyloidosi darzalex cyclophosphamide/bortezomib/dexamethason
cybord vs cybord alon expect trial filabl regul
approv al darzalex first indic beyond mm forecast peak sale
al probabl success
acut lymphoblast leukemia type blood cancer result excess
product lymphocyt white blood cell bone marrow affect product
red blood cell white blood cell platelet common treatment includ
chemotherapi stem cell transplant recur genmab current recruit
phase dephinu studi dara vincristin prednison doxorubicin
forecast peak sale probabl success
nkt-cell lymphoma nkt-cell lymphoma rare lymphoma associ epstein-barr
viru ebv typic localis nose volan fulli recruit forecast peak
sale nkt-cell lymphoma probabl success
solid tumour note given darzalex combin anoth
drug solid tumour set howev highlight studi second-
line non-smal cell lung cancer darzalex plu tecentriq stop futil
show increas death activ arm second combin trial
investig darzalex plu antibodi
indicationphasetri nametherapypeak salesprobabilitymultipl myelomaapprovedmonotherapi multipl myelomaphas amyloidosi phase syndrom phase lymphoblast leukemia phase vincristin prednison lymphomaphas tumoursphas charl martineau univers toronto april
multipl myeloma also halt figur show on-going solid tumour combin
trial darzalex next set combin opdivo expect complet
current attribut valu solid tumour darzalex
figur solid tumour trial combin
competit intens unlik replac darzalex
multipl myeloma treatment landscap evolv significantli past year
follow introduct proteasom inhibitor velcad kyproli pomalyst emplic
immunomodulatori drug imid revlimid mab darzalex figur follow
darzelex approv think becom backbon treatment mm patient
figur multipl myeloma treatment landscap time
howev number advanc pipelin could compet darzelex
domin figur highlight key pipelin product mm genmab investor
sarclisa isatuximab price favour uniqu
efficaci broadli line darzalex phase icaria-mm data sarclisa isa
combin pomalidomid /dexamethason vs pd patient difficult-to-
treat relapse/refractori mm show similar data darzalex set sarclisa isapd
show median progress free surviv month vs pd month
rel risk reduct consist across major
subgroup overal respons rate isapd vs pd
overal surviv os immatur show trend improv hr
durat infus improv current darzalex intraven
infus subcutan darzalex horizon highlight median sarclisa
intraven infus durat hour first infus hour subsequ
infus compar darzalex first infus approxim hour
subsequ infus hour
drugtargetcompani highest develop stagecommentssarclisa approv competitor launch difficult-to-treat relapse/refractori multipl myeloma underway asia morphosi continu evalu develop option indic us eubelantamab mafodotin anti-bcma bispecificgskfiledfirst anti-bcma fda prioriti review grant januari relaps refractori multipl myeloma gsk wide develop plan move belantamab mafodotin treatment anti-bcma tjnjphase collabor chines compani nanj legend develop celgeneidecabtagen vicleucel anti-bcma tbluebird/bmyphas bcma -t molecul multipl myeloma bite molecul multipl myeloma developmentequuleusiia-mmdpdisapd vs pdorr median month rate darzalex dexamethason isa isatuxumab charl martineau univers toronto april
price appear cheaper darzalex first dose sarclisa
list price five pack vial believ annual
darzalex cost first year infus cost drop
year infus note revlimid list price pomolyst
cs view sarclisa isatuximab data icaria-mm look promis efficaci
safeti broadli line darzalex believ find role altern darzalex
see anyth data differenti darzalex becom first
choic least data typic combin pomolyst combin
less prefer option prescrib multipl sarclisa trial pipelin
differenti io combin cemiplimab kyproli howev seen
combin revlimid velcad shown best data rrm
relaps remit multipl sclerosi suggest sanofi comfort pitch
isatuximab patient intoler product
discontinu multipl myeloma us eu
commerci launch asia antibodi develop
morphosi i-mab biopharma china-bas biotech compani current phase
trial relaps remit multipl myeloma taiwan us eu morphosi
discontinu develop multipl myeloma follow discontinu
partnership celgen
efficaci bcma-target therapi impress
like reserv last-lin therapi due safeti concern
bcma efficaci impress albeit earli stage number b-cell
matur antigen bcma target antibodi car-t chimer antigen receptor
cell develop advanc interest data gsk
relaps remit multipl myeloma patient efficaci look
 belantamab mafodotin bmca bispecif belantamab mafodotin potenti first
anti-bcma treatment approv data heavili pretreat patient
show respons rate patient complet respons cr
anoth patient good partial respons vgpr dreamm-
pivot data patient line therapi use file
relapsed/refractori multipl myeloma show orr
 bcma bispecif bispecif antibodi bind bcma malign
plasma cell cell mechan bring cell close proxim
target tumour cell howev note one death cytokin releas
syndrom recent earli data phase show
orr rate complet remiss highest dose
bcma -t idecabtagen bcma-target t-cell
therapi karmma studi show overal respons rate
complet remiss high dose cell durat
respons month
bcma car-t also car-t therapi target
bcma initi data phase trial show patient
respond median follow-up six month
bite bispecif anti-b-cel matur antigen t-cell engag
bite induc respons multipl myeloma earli data show
respons rate dose
figur pipelin bcma data relaps remit multipl myeloma patient
bcma side-effect profil tough earlier line therapi especi multipl
myeloma occur elderli popul
 bcma antibodi dreamm belantamab mafodotin studi ocular toxic
keratopathi defin corneal epithelium chang seen patient
appear manag regular ophthalmolog exam dose
modif believ limit use earlier line therapi
seen ocular toxic car-t bcma studi
addit rate thrombocytopenia low blood platelet count high
 bcma car-t cytokin releas syndrom one common
advers effect idecabtagen studi believ could
also hinder uptak earlier line therapi given averag age multipl
myeloma diagnosi year old typic fragil younger
cancer patient one death idecabtagen studi due
car-t technolog immedi applic everyon commun
set highlight car-t therapi requir patient undergo apheresi
collect cell follow manufactur process gene
chimer antigen receptor insert cell car-t cell infus
back patient process take week commun hospit
well set term infrastructure/logist process given lack
conveni believ car-t therapi remain use salvag popul
darzalex move front-lin therapi
next month expect multipl pipelin news flow could valid
genmab becom commerci biotech allow investor move beyond darzalex
invest thesi see figur key catalyst highlight promis
candid appear tisotumab vedotin probabl success
promis cervic cancer enapotamab vedotin solid tumour
bispecif phase asset b-cell malign
shown interest encourag earli data tisotumab enapotamab vedotin
develop collabor seattl genet genmab like opt co-
promot us advanc tisotumab vedotin genmab said
expect secur partner give product valid
drugtechnologytarget/sindication/sphasepospeak salespartnercommentscerv vedotinadcaxl uniqu rtk solid geneticsseattl genet receiv mileston mid-to-high singl digit royaltyeocoritamab activ seek sale profit splittisotumab vedotinadctissu factor tf proteinseattl approv ofatumumab vedotin us approv mid readoutsenapotamab vedotin feb primari complet completitorspolivi dlbcl readouttisotumab vedotincerv pivot data readout/poss fda filingofatumumabmsu approv pdufa vedotinsolid tumour japan readoutenapotamab data readoutepcoritamab malignanciesfollow expans startduobodi initi data readoutepcoritamab malignanciesannouc partnershipdarazalexmmsubq us approv mid charl martineau univers toronto april
sale forecast vs consensu
npv npv
cs comment potenti pivot data expect potenti launch
earli think tisotumab vedotin potenti new gold standard
ovarian cancer result reflect data seen thu far
tisotumab vedotin target tissu factor tf protein express mani
solid tumour includ cervic ovarian prostat bladder esophag endometri lung
cancer gener associ poorer outcom consist genmab mab
leverag seattl genet cleavabl linker technolog cytotox drug monomethyl
auristatin mmae see figur molecular schemat approach may offer
target deliveri cytotox agent bolster efficaci lower risk system
genmab develop collabor split cost
futur revenu latter lead commercialis us canada mexico
understand genmab want opt co-promot us
take commerci lead north america right salesforc place
alreadi genmab intend leverag
figur schemat tisotumab vedotin
develop date focus harder-to-treat late-stag solid tumour
understand compani ambit move earlier line therapi figur
full pipelin on-going studi advanc trial cervic
ovarian cancer phase ii studi set read believ
data recurr metastat cervic cancer could form basi first
genmab proprietari drug approv
figur on-going trial tisotumab vedotin
indic studi complet enrol
potenti lead efficaci refractori cervic cancer
current standard care keytruda provid orr mo month
cervic cancer lead indic tisotumab vedotin standard
care shift
immunotherapi chemo-refractori set nccn guidelin recommend use
keytruda patient
chemotherapy/avastin
cervic cancer fourth commonli occur cancer women
women expect diagnos year us screen programm
result earlier detect cancer estim suggest
patient diagnos late-stag diseas metastat stage prognosi poor
chemotherapi provid respons patient surviv
keytruda current benchmark ovarian cancer grant fda
approv posit patient fail least one line
chemotherapi approv grant data small cohort patient
studi show orr cr
patient mo month mdor yet reach rang
month merck two on-going studi metastat keynote-
local advanc could expand label includ earlier cervic cancer
patient data expect respect
diseasestagedevelopmentphasepreclinicalii/iiiiiiicerv cancerrecurr stageivb keytruda/avastin combo tumourslocallyadvanc metastat complet sept complet june complet aug complet dec complet apr charl martineau univers toronto april
sever drug phase develop cervic cancer
publish encourag respons data thu far see figur howev small patient
number look data particularli safeti given high toxic typic
seen combin cell-bas therapi
figur data comparison on-market pipelin cervic cancer drug
earli clinic result show tisotumab vedotin better respons keytruda
genmab/seattl genet innovatv basket studi tisotumab vedotin
demonstr slightli higher orr vs keytruda heavili pretreat
cervic cancer popul patient median dor month
publish lancet
note high rate grade nose bleed epistasix fatigu
nausea alopecia one patient death associ studi
treatment consist chemotherapi one ae note conjunct
occur patient grade patient suffer grade wors
conjunct innovatv studi ae commonli
seen current standard care keytruda although case tisotumab mild
presum manag
data follow-on innovatv studi expect read
result like pivot studi complet recruit patient
studi show similar result studi would expect
compani engag regul acceler assess earli
genmab also studi tisotumab vedotin refractori late-stag cervic cancer
combin keytruda avastin phase studi
collabor merck variou academ group includ engot studi
expect enrol patient data expect accord clinicaltri gov
given high rate respons seen monotherapi refractori set
possibl combin could produc even greater respons untreat fitter
patient possibl could see safeti run data prior howev
timelin disclos either compani
approvedpipelinekeytrudabalstilimab metastat cervic cancer patient cervic cervic cancerarmkeytruda monocombo opdivo low dose yervoycombo opdivo high dose yervoybalstilimab nr nr musculoskelet pain diarrhea pain grade grade metastat cervic cancer comersbristol myer charl martineau univers toronto april
view metastat cervic cancer potenti global peak sale opportun
tisotumab assum po launch sale profit split
two compani pharmavalu cervic npv dkk genmab
model patient us europ
row diagnos cervic cancer year
estim metastat diseas major
elig therapi base low respons rate seen chemotherapi studi
assum durat therapi month base data price similar
current immunotherapi price expect peak penetr us
europ modest penetr row assum tisotumab launch
second market behind keytruda see figur
figur sale potenti cervic cancer
ovarian cancer solid tumour may offer limit addit
beyond cervic cancer tisotumab vedotin also earli develop platinum resist
ovarian cancer proc solid tumour
ovarian cancer landscap crowd leav littl room tisotumab seiz
sizeabl share market
expect limit commerci opportun platinum-resist ovarian cancer set given
strength exist therapi parp inhibitor becom well
embed clinic practic alreadi nccn prefer regimen set
on-going innovatv phase dose escal studi expect read
posit expect compani would need run studi
launch earliest
therefor see limit increment opportun indic model global
peak sale po pharmavalu npv
us europerowno diagnos cervic stage iv ellig patient sale charl martineau univers toronto april
solid tumour opportun still mani year away efficaci data yet avail
support develop
beyond gynaecolog tumour also two earli phase basket studi on-going solid
tumour non-pivot
innovatv current enrol local advanc metastat patient
colorect nsclc pancreat squamou head neck cancer us
europ studi assess dose expect complet
innovatv japan-onli dose escal studi finish recruit
februari data studi expect septemb expect
like use inform futur pivot studi cervic cancer
would expect compani run separ pivot trial tumour type
adequ signal seen would expect launch earli global addit
tumour type japanes cervic cancer sale alreadi factor global forecast
detail
see small increment opportun peak sale po addit
enapotamab vedotin potenti refractori
npv dkk npv
cs comment follow-up data enapotamab vedotin nsclc expect read
enapotamab vedotin humax-axl- second earlier-stag develop
partnership molecul wholly-own genmab leverag
technolog in-licens seattl genet use cytotox agent
tisotumab mab target uniqu receptor tyrosin kinas rtk
express varieti tumour type includ nsclc known neg prognost
associ drug resist overexpress indic resist
immun checkpoint inhibitor small molecul drug i-o refractori patient area high
unmet need hand approv small molecul therapi target along
pathway target cabometyx ipsen/exelexi xospata astella
licens agreement seattl genet entitl receiv potenti
mileston mid-to-high single-digit royalti world-wide net sale genmab seattl
genet also right exercis option increas royalti low
exchang reduc mileston payment
clinic result still earli show initi sign promis i-o refractori
genmab run larg trial rang relapsed/refractori advanc
solid tumour includ nsclc top-line data phase part studi first
present world confer lung cancer link abstract
nsclc without egfr mutat rearrang fail
prior line therapi includ chemotherapi inhibitor
treat enapotamab vedotin everi three week orr
diseas control rate cr pr sd patient biopsi
evalu biomark test posit term safeti
common fatigu constip two patient led dose
reduct given heavili pre-treat popul see result encourag
toler manag high unmet need popul await data
explor full commerci potenti drug
expect follow-up data nsclc expans cohort studi
compani also suggest could see initi data melanoma cohort later
year overal studi expect complet accord clinicaltri gov
commerci opportun may constrain biomarker-select popul
understand compani work ventana potenti companion diagnost
axl-rel biomark could complic potenti futur launch
ascrib global peak opportun po launch earliest
believ unlik enapotamab vedotin use earlier line therapi
bispecif b-cell malign
npv dkk npv
cs comment genmab expect secur strong commerci partner announc
partnership expect earli data show potenti best-in-class vs roch
regeneron differenti subcutan formul like greater potenc
follow-up data dose escal studi anticip later year
high interest epcoritamab partnership expect
epcoritamab genmab proprietari bispecif antibodi target
leverag genmab duobodi technolog drug current develop
genmab alon although genmab activ seek develop commerci
partner ambit share steer committe experi
hematolog malign space recent compani call highlight high interest
attract negoti on-going announc expect second half year
believ sign deal commerci experi would valid product well
receiv investor
tumour-associ antigen found b-cell antigen found t-cell
simultan bind site use bispecif antibodi result redirect t-cell
activ b-cell promot proliferation/expans pre-exist t-cell may
enhanc b-cell deplet produc greater efficaci therapi alon see figur
develop date focus later-lin dlbcl understand compani
aspir expand develop programm wider rang tumour type
move earlier line therapi
figur schemat epcoritamab
protein commonli express b-cell malign includ cll
nhl dlbcl fl follicular leukemia mcl mantl cell leukemia
success target therapeut mani year roch rituxan gazyva
howev despit effect therapi mani patient still relaps requir
dlbcl common type b-cell non-hodgkin lymphoma nhl repres
heterogen group diseas variabl outcom overal dlbcl cancer tend
fast grow aggress natur treatment patient achiev cure
still experi refractori diseas initi treatment
first-lin treatment stage iii-iv diseas typic r-chop rituximab combin
chemotherapi agent cyclophosphamid doxorubicin vincristin prednison
patient relaps r-chop autolog stem-cel transplant asct standard
care patient elig howev given cancer often
present older patient popul mani patient fact inelig transplant
furthermor greater half patient receiv asct still relaps
patient novel therapeut approach critic figur indic
patient flow dlbcl
figur indic patient flow dlbcl
follicular lymphoma also type nhl slower grow vs dlbcl hard
cure often recur less sever case treatment may requir sever year
patient sever diseas treatment similar dlbcl rituxan r-chop use
front-lin set relaps set kinas inhibitor shown benefit
mani therapi investig use inhibitor btk
inhibitor see opportun new therapi later-lin set
therapeut landscap late-lin dlbcl rapidli evolv still see
plenti unmet need particularli post car-t set
numer chemo-immunotherapi treatment regimen approv
recent year relaps refractori patient relaps choic
patient becom increasingli limit late-lin patient car-t chimer antigen
receptor cell therapi yescarta gilead/kit kymriah novarti recent
roch target polivi avail
expect car-t therapi compress time commerci
feasibl individu car-t therapi realiz clinic practic patient
often experi long wait time median day accord kymriah/yescarta
smpc turnaround treatment report failur rate
manufactur furthermor patient treat specialist centr due
associ high risk sever toxic cytokin releas syndrom neurotox
therefor estim peak bispecif r/r
dlbcl market receiv car-t therapi due logist manufactur
challeng high cost therapi
first-lin treatmentcurefirst eligibletranspl ineligiblepati respond salvag therapi proceed asctpati respond salvag therapycurenot salvag charl martineau univers toronto april
polivi strong us launch date rapidli move front-lin set
roch polivi polatuzmab vedotin-piiq target current
use set bispecif aim use futur
drug launch us dlbcl base pivot data
studi show complet respons rate polivi br vs br alon
orr patient treat polivi patient dor
least month dor least month
roch report strong us launch thu far use dlbcl strong
bridg therapi given administ outpati set off-the-shelf
format roch ambit move therapi up-front fourfold
patient treat r/r studi earlier-lin use polivi on-going data
expect fulli recruit polarix trial polivi r-chop
earli data studi show orr dlbcl
peak bispecif expect polivi still hold r/r
genmab catch bispecif competitor
better product potenti earli sure
roch regeneron ahead genmab iv formul
roch regeneron develop bispecif drug r/r
dlbcl along develop genmab data studi
publish meet alongsid first report clinic data
genmab studi figur figur data comparison
roch furthest ahead develop vs peer bispecif monsunetuzumab
far demonstr earli durabl respons patient relaps
diseas includ patient receiv prior car-t therapi dose escal studi
complet respons rate aggress nhl
indol nhl respect moreov durabl encourag
remain remiss month come therapi phase studi
on-going assess monsunetuzumab monotherapi combin
tecentriq/chop/polivi roch assum launch possibl assign
global peak indic po roch also bispecif
tcb also assess nhl indic current
regeneron close behind roch develop
note higher report rate cytokin releas syndrom vs roch molecul
may prove troublesom rate replic larger studi howev
efficaci r/r dlbcl particularli car-t refractori patient look encourag
orr cr patient treat mg dose higher biotech
analyst estim peak peak launch
also bispecif earli clinic develop
plamotamab r/r nhl initi data present show orr
cr evalu patient safeti look similar regeneron
evalu consensu estim assum launch
epcoritamab may offer cleaner safeti profil
genmab bispecif one develop subcutan formul
could conveni competitor come market anim studi sc
reduced/delay cmax level reduc peak cytokin level plasma vs iv in-vitro
data show higher potenc vs three bispecif
develop posit genmab potenti best-in-class
term clinic data genmab last publish data studi
dose escal studi enrol patient dlbcl follicular
lymphoma patient heavili pretreat dlbcl patient
receiv car-t patient dlbcl cohort respons fl
respons therapi take care draw detail cross trial
comparison given small patient number encourag clinic result
clearli show drug anti-tumour activ heavili pre-treat popul
safeti rate cytokin releas syndrom key focu drug
particularli grade event given measur need place manag
associ car-t therapi see bi-specif
report grade event howev caution draw concret
conclus given small trial size broadli dose limit toxic
observ maximum toler dose yet reach dose escal
on-going potenti follow data expect publish later year
efficaci safeti result seen thu far replic larger studi see
potenti epcoritamab best-in-class despit like least class
market ascrib peak po possibl launch earli
npv pharmavalu npv
figur data comparison rate bi-specif
figur efficaci data comparison bispecif
roch mosunetezumab regeneron grade diagnosisindol nhlall flaggress nhlall dlbcl/trfl prior car-tfl gr without tdlbcl tmclmzlr/r mosunetezumab genmab charl martineau univers toronto april
esg measur less critic biopharma
despit esg becom increasingli import invest factor fund topic
major focu healthcar partli industri heavili
regul eg fda ema investor focu biopharma particular tend focu
social govern compon esg
sinc genmab process transit produc market drug
date limit relev data avail analysi given lead market
darzalex novarti lead market ofatumumab compon look
three part corpor govern account qualiti ceo pay use credit suiss
genmab corpor govern larg line
peer differ
genmab publish statutori corpor govern report annual report overal
appear follow govern recommend region industri howev
note area govern rule appear differ versu industri norm
take-over bid certain circumst genmab right reject take-over bid
without consult sharehold although govern rule state action
determin case-by-cas basi due consider interest
shareholders/oth stakehold may view unattract investor
board remuner genmab compens board member includ restrict
stock unit rsu form equiti compens whilst occur often biotech
help attract retain qualifi board member highlight less common
potenti conflict interest board members/affect board independ
rsu award execut manag vest three year grant
driven strengthen differenti pipelin part includ daratumumab
ceo compens appear averag vs peer
execut bonus partli driven darzalex sale
holt analysi indic genmab ceo receiv rel higher compens
vs econom profit three-year time-frame compar compani us
european peer group disclos compens report dr van de
winkel receiv dkk dkk fix pay benefit
highlight genmab annual bonu plan scorecard execut manag
includ darzalex-rel financi goal darzalex sale meet exceed financi
guidanc year threshold level financi perform requir
financi guidanc goal meet oper expens target genmab alloc
weight two financi goal disclos proport
weight alloc darzalex sale target may view debat
assumpt given genmab receiv royalti sale darzalex
manag direct influenc sale driven
encourag remain weight bonu plan alloc
company-strateg goal mostli concentr achiev target proprietari
pipelin product see potenti unlock futur valu sharehold
figur holt analysi ceo pay level vs econom profit genmab versu us european peer
note holt econom profit repres econom earn firm ep proport spread compani return capit cost capit firm earn
cost capit ep zero
grey european peer us peer orang us european peer
genmabbluebirdalynylambiomarinexact sciencesseattl geneticsalkermesneurocrineagiosexelixisionisunit therapeuticsnektarargenxmorphosysgenusdechragalapagosabcamvertex year level ceo pay year level econom profit charl martineau univers toronto april
account qualiti look good holt vs eu specialti
region peer
holt look qualiti compani disclosur rank compani across number
